Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beximco Completes Acquisition Of Sanofi Bangladesh

Company Takes Majority Stake In Sanofi Bangladesh For Just Over $50m

Executive Summary

Beximco has completed its acquisition of a majority stake in Sanofi Bangladesh to “expand its core capabilities and product offerings.” With its second major acquisition under its belt, Beximco said that it plans to continue its diversification and expansion.

You may also be interested in...



Inflation And Local Currency Depreciation Drag Down Beximco’s Bottom Line

Rising inflation and the depreciation of the Bangladeshi taka have taken their toll on Beximco’s profits even as revenue has continued to rise at the firm.

Beximco Faces Potentially Rough Ride In The Face Of Macroeconomic Headwinds

Following a year of impressive business developments, economic developments such as a depreciating local currency threaten to knock Beximco off-course.

Accord And Sandoz Lead Victories At GGB Awards 2022

Accord and Sandoz were the big winners at the Global Generics & Biosimilars Awards 2022 in Frankfurt, with other firms recognized including Beximco, Centrient, Dr Reddy’s, Eurofarma, Samsung Bioepis, Shanghai Henlius Biotech and Stada, as well as the US Biosimilars Forum.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel